Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

Summary

The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing corneal transplantation.

Timeline

Start

2008-10

Primary completion

2011-08

Completion

2012-03

Drugs

Indications